Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPINION: olaparib maintenance monotherapy in platinum-sensitive recurrent ovarian cancer without germline BRCA mutation
MOH_2018-03-13_002244Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jan 2018; status: recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2018-03-13_002244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-13_002244.